medius KLINIKEN gGmbH
- Address
- lock Available on a paid plan
medius KLINIKEN gGmbH - Inflammatory Bowel Disease Research
medius KLINIKEN gGmbH is actively engaged in advancing therapeutic options for patients with inflammatory bowel disease, with a particular focus on ulcerative colitis. The center participates in multi-phase clinical investigations evaluating novel pharmacological interventions designed to improve disease management and patient outcomes in moderate to severe presentations of this chronic inflammatory condition.
- Evaluation of ABX464 for inducing and maintaining clinical remission in ulcerative colitis
- Treatment strategies for moderately to severely active ulcerative colitis
- Novel therapeutic approaches for inflammatory bowel disease management
The research conducted at medius KLINIKEN gGmbH emphasizes both induction and maintenance therapy protocols, reflecting a comprehensive approach to ulcerative colitis treatment. Through participation in the ABTECT clinical trial program, the center contributes to the development of innovative therapies that may offer new hope for patients who require effective long-term disease control and clinical remission.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in medius KLINIKEN gGmbH
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis | Abivax | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obefazimod | 2 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.